Volume 10, Issue 4 (12-2022)                   JoMMID 2022, 10(4): 153-156 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shukla S, Kamini K, Gupta B, Bahadur S, Kalhan S, Gupta M. Parameters of Coagulation in COVID-19 Patients: A Correlation with Clinical Severity. JoMMID 2022; 10 (4) :153-156
URL: http://jommid.pasteur.ac.ir/article-1-453-en.html
Government Institute of Medical Sciences, Gautam Buddha Nagar
Abstract:   (416 Views)
Introduction: COVID-19 infection can be complicated by coagulation derangement and a high risk of thromboembolic episodes. Our study aimed to investigate coagulation parameters in COVID-19 patients and their correlation with clinical severity. Methods: We analyzed coagulation parameters PT, APTT, D-Dimer, and Fibrinogen in 98 RT-PCR-confirmed COVID-19 patients admitted to the Government Institute of Medical Sciences, Gautam Buddha Nagar, Uttar Pradesh, India. Results: This study involved 69 males (70.50%), and 29 (29.5%) were females. The mortality rate was 6.12% (n= 06). Forty-six patients (46.94%) had comorbidities. Thirty-four patients had elevated PT, and 7 had high APTT, whereas D-dimer and fibrinogen levels were raised in 68 and 61 patients, respectively. Among all four parameters, D-Dimer levels were significantly associated with disease severity. Conclusion: Derangement of D-dimer levels is significantly associated with disease severity in COVID-19 infection.
Full-Text [PDF 497 kb]   (197 Downloads)    
Type of Study: Original article | Subject: Diagnostic/screening methods and protocols
Received: 2022/03/15 | Accepted: 2022/12/10 | Published: 2022/12/31

1. World health organization, Novel Coronavirus (Covid-19) situation. Available: https://covid19.who.int/
2. Jin X, Duan Y, Bao T, Gu J, Chen Y, Li Y, et al. The values of coagulation function in COVID-19 patients. PLoS One. 2020; 15 (10): e0241329. [DOI:10.1371/journal.pone.0241329]
3. W.J.Guan, Z.Y.Ni, Y.Hu, W.H Liang, C.Q Ou, J.x He, et al. Clinical characteristics of coronavirus disease 2019 in China. NEJM. 2020; 382 (18): 1708-20. [DOI:10.1056/NEJMoa2002032]
4. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan China. Int J Infect Dis. 2020; 91: 264-6 [DOI:10.1016/j.ijid.2020.01.009]
5. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 3 (10): 265-9. [DOI:10.1038/s41586-020-2008-3]
6. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020; 92 (5): 461-3. [DOI:10.1002/jmv.25711]
7. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844-7. [DOI:10.1111/jth.14768]
8. Clinical Management Protocol: Covid-19. Version-3: Mohfw. 13.06.2020.
9. Dacie and Lewis Practical Hematology. 12th Edition: Barbara J Bain, Imelda Bates, Michael A. Laffan; 2017.
10. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844-7. [DOI:10.1111/jth.14768]
11. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020; 127: 104362. [DOI:10.1016/j.jcv.2020.104362]
12. Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. Biomed Res Int. 2020; 2020: 6159720. [DOI:10.1155/2020/6159720]
13. Martín-Rojas RM, Pérez-Rus G, Delgado-Pinos VE, Domingo-González A, Regalado-Artamendi I, Alba-Urdiales N, et al. COVID-19 coagulopathy: An in-depth analysis of the coagulation system. Eur J Haematol. 2020; 105 (6): 741-50. [DOI:10.1111/ejh.13501]
14. Luo HC, You CY, Lu SW, Fu YQ. Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol. 2021; 100 (1): 45-52. [DOI:10.1007/s00277-020-04305-x]
15. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130 (5): 2620-9. [DOI:10.1172/JCI137244]
16. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020; 58: 1116-20. [DOI:10.1515/cclm-2020-0188]
17. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020; 18 (7): 1548-55. [DOI:10.1111/jth.14872]
18. Ozolina A, Sarkele M, Sabelnikovs O, Skesters A, Jaunalksne I, Serova J, et al. Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study. Front Med (Lausanne). 2016; 28; 3: 64. [DOI:10.3389/fmed.2016.00064]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.